+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Sumitomo Dainippon

  • ID: 5357318
  • Company Profile
  • January 2021
  • 47 pages
  • Datamonitor Healthcare
The publisher explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Sumitomo Dainippon is projected to see growth until the loss of exclusivity for Latuda, while recent additions to the late-stage pipeline will offset some of the revenue declines.
  • Key themes - [1] Sumitomo Dainippon’s topline revenues are affected primarily by Latuda, which is forecast to grow until 2023 and then see a significant decline due to its patent expiry [2] Strategic alliance with Roivant brings relugolix and vibegron into Sumitomo Dainippon’s portfolio.
Model updates (28 October 2020)
  • Galvus forecast adjusted higher due to launch trend of Equa in Japan
  • Trulicity forecast adjusted higher due to continued market share gains
  • APL-130277 name changed to Kynmobi
  • Relugolix forecast added
  • Vibegron forecast added.
Model updates (29 October 2019)
  • Alvocidib launch delayed
  • APL-130277 launch delayed
  • Napabucasin launch added.
Model updates (14 August 2019)
  • Metgluco forecast adjusted higher due to company guidance
  • Surepost forecast adjusted lower due to company guidance
  • Trulicity forecast adjusted higher due to company guidance
  • Lonasen forecast adjusted lower due to generic competition
  • Latuda forecast adjusted lower due to company guidance
  • Rethio forecast added
  • Imeglimin forecast added.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll